Document:

EXHIBIT 10.1

SANGSTAT MEDICAL CORPORATION

2002 STOCK OPTION PLAN

	
I.

	
PURPOSE OF THE PLAN

	
 

	
 

	
 

	
A.

	
This 2002 Stock Option Plan (the “Plan”) is intended to promote the interests of SangStat Medical Corporation, by providing (i) employees (including officers) of the Corporation (or any Parent or Subsidiary) (each,
as hereinafter defined below) who are responsible for the management, growth and financial success of the Corporation (or any Parent or Subsidiary), (ii) non-employee members of the Board (as defined below) or the board of directors of any Parent or Subsidiary and
(iii) consultants and other independent contractors who provide valuable services to the Corporation (or any Parent or Subsidiary) with the opportunity to acquire a proprietary interest, or otherwise increase their proprietary interest, in the Corporation as an
incentive for them to remain in the service of the Corporation (or any Parent or Subsidiary).

	
 

	
 

	
 

	
 

	
B.

	
Subject to stockholder approval, the Plan shall become effective as of March 6, 2002, the date on which the Plan was approved by the Board.  Such date is hereby designated as the Effective Date of the Plan.

	
 

	
 

	
 

	
 

	
C.

	
The Plan shall serve as the successor to the Corporation’s 1993 Stock Option Plan (the “Predecessor Plan”).  The Predecessor Plan will be terminated upon stockholder approval of the Plan, and no further
stock option grants shall be made from the Predecessor Plan from and after the date of stockholder approval of the Plan.  All options outstanding under the Predecessor Plan immediately prior to the termination of the Predecessor Plan will be incorporated into
this Plan and shall accordingly be treated as outstanding options under the Plan.  However, each outstanding option so incorporated shall continue to be governed solely by the express terms and conditions of the instrument evidencing such grant, and no provision
of this Plan shall be deemed to affect or otherwise modify the rights or obligations of the holders of such incorporated options with respect to their acquisition of shares of the Corporation’s Common Stock thereunder.

	
 

	
 

	
 

	
II

	
DEFINITIONS

	
 

	
 

	
 

	
 

	
A.

	
For purposes of the Plan, the following definitions shall be in effect:

	
 

	
 

	
 

	
 

	
 

	
1.

	
Board: the Corporation’s Board of Directors.

	
 

	
 

	
 

	
 

	
 

	
 

	
2.

	
Cause: means, unless otherwise defined by the Optionee’s individual stock option agreement or contract of employment or service, any of the following: (1) the Optionee’s theft, dishonesty, or falsification of any
Corporation documents or records; (2) the Optionee’s improper use or disclosure of the Corporation’s confidential or proprietary information; (3) any action by the Optionee which has a detrimental effect on the Corporation’s reputation or business;
(4) the Optionee’s failure or inability to perform any reasonable assigned duties after written notice from the Corporation of, and a reasonable opportunity to cure, such failure or inability; (5) any material breach by the Optionee of any employment or service
agreement between the Optionee and the Corporation, which breach is not cured pursuant to the terms of such agreement; or (6) the commission of acts constituting, the indictment or conviction of, or plea of guilty or nolo contendere for, any commission of a felony or
other crime arising in the conduct of the Optionee’s employment or service with the Corporation, which may impair the Optionee’s ability to perform his or her duties with the Corporation, or which involves theft, misrepresentation

 

	
 

	
 

	
 

	
or dishonesty.  Determination of Cause shall be made by the Plan Administrator in its sole discretion.

	
 

	
 

	
 

	
 

	
 

	
 

	
3.

	
Change in Control: a change in ownership or control of the Corporation effected through either of the following transactions:

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
a.

	
any person or related group of persons (other than the Corporation or a person that directly or indirectly controls, is controlled by, or is under common control with, the Corporation) directly or indirectly acquires
beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities pursuant to a tender or exchange offer made directly to
the Corporation’s stockholders; or

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
b.

	
there is a change in the composition of the Board over a period of thirty-six (36) consecutive months or less such that a majority of the Board members ceases, by reason of one or more proxy contests for the election of Board
members, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described
in clause (A) who were still in office at the time such election or nomination was approved by the Board.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
4.

	
Code:  the Internal Revenue Code of 1986, as amended.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
5.

	
Committee: means any committee the Board may appoint to administer the Plan.  To the extent necessary and desirable, the Committee shall be composed entirely of individuals who meet the qualifications referred to in
Section 162(m) of the Code and Rule 16b-3 of the 1934 Act.  If at any time or to any extent the Board shall not administer the Plan, then the functions of the Board specified in the Plan shall be exercised by the Committee.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
6.

	
Common Stock: shares of the Corporation’s common stock.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
7.

	
Corporation: means SangStat Medical Corporation, a Delaware corporation (or any successor corporation).

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
8.

	
Corporate Transaction: the consummation of any of the following stockholder-approved transactions to which the Corporation is a party:

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
a.

	
a merger or consolidation in which the Corporation is not the surviving entity, except for a transaction the principal purpose of which is to change the State in which the Corporation is incorporated,

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
b.

	
the sale, transfer or other disposition of all or substantially all of the assets of the Corporation in complete liquidation or dissolution of the Corporation, or

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
c.

	
any reverse merger in which the Corporation is the surviving entity but in which securities possessing more than fifty percent (50%) of the total combined voting power of the Corporation’s outstanding securities are
transferred to a person or persons different from those who held such securities immediately prior to such merger.

2

	
 

	
 

	
9.

	
Employee: an individual who performs services while in the employ of the Corporation or any Parent or Subsidiary, subject to the control and direction of the employer entity not only as to the work to be performed but also as
to the manner and method of performance.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
10.

	
Fair Market Value: the fair market value per share of Common Stock determined in accordance with the following provisions:

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
a.

	
If the Common Stock is not at the time listed or admitted to trading on any national stock exchange but is traded on the Nasdaq National Market, the Fair Market Value shall be the closing selling price per share on the date in
question, as such price is reported by the National Association of Securities Dealers on the Nasdaq National Market or any successor system.  If there is no reported closing selling price for the Common Stock on the date in question, then the closing selling
price on the last preceding date for which such quotation exists shall be determinative of Fair Market Value.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
b.

	
If the Common Stock is at the time listed or admitted to trading on any national stock exchange, then the Fair Market Value shall be the closing selling price per share on the date in question on the exchange determined by the
Plan Administrator to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange.  If there is no reported sale of Common Stock on such exchange on the date in question, then the Fair
Market Value shall be the closing selling price on the exchange on the last preceding date for which such quotation exists.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
11.

	
Hostile Take-Over: a change in ownership of the Corporation effected through the direct or indirect acquisition by any person or related group of persons (other than the Corporation or a person that directly or indirectly
controls, is controlled by, or is under common control with, the Corporation) of beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the
Corporation’s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation’s stockholders which the Board does not recommend such stockholders to accept.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
12.

	
Incentive Option: a stock option that meets the requirements of an “incentive stock option” within the meaning of Section 422 of the Code, or any successor provision.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
13.

	
1934 Act:  the Securities Exchange Act of 1934, as amended from time to time.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
14.

	
Optionee:  any person to whom an option or stock appreciation right is granted under the Plan.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
15.

	
Parent: any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, provided each such corporation in the unbroken chain (other than the Corporation) owns, at the time of the
determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
16.

	
Plan Administrator:  the Committee in its capacity as the administrator of the Plan.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
17.

	
Permanent Disability or Permanently Disabled: the inability of the Optionee to engage in any substantial gainful activity by reason of any medically determinable physical or

3

	
 

	
 

	
 

	
mental impairment expected to result in death or to be of continuous duration of twelve (12) months or more.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
18.

	
Service:  the performance of services on a periodic basis to the Corporation (or any Parent or Subsidiary) in the capacity of an Employee, a non-employee member of the board of directors or an independent consultant or
advisor, except to the extent otherwise specifically provided in the applicable stock option agreement.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
19.

	
Subsidiary:  each corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, provided each such corporation (other than the last corporation) in the unbroken chain owns,
at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
20.

	
Take-Over Price:  the greater of (a) the Fair Market Value per share of Common Stock on the date the option is surrendered to the Corporation in connection with a Hostile Take-Over or (b) the highest reported price per
share of Common Stock paid by the tender offeror in effecting such Hostile Take-Over.  However, if the surrendered option is an incentive stock option under the Federal tax laws, the Take-Over Price shall not exceed the clause (a) price per share.

	
 

	
 

	
 

	
 

	
 

	
III.

	
ADMINISTRATION OF THE PLAN

	
 

	
 

	
 

	
A.

	
The Plan shall be administered by the Committee.  Members of the Committee shall serve for such period of time as the Board may determine and shall be subject to removal by the Board at any time.

	
 

	
 

	
 

	
 

	
B.

	
The Committee as Plan Administrator shall have full power and authority (subject to the express provisions of the Plan) to establish rules and regulations for the proper administration of the Plan and to make such
determinations under, and issue such interpretations of, the provisions of the Plan and any outstanding option grants thereunder as it may deem necessary or advisable.  Decisions of the Plan Administrator shall be final and binding on all parties who have an
interest in the Plan or any outstanding option thereunder.

	
 

	
 

	
 

	
IV.

	
OPTION GRANTS

	
 

	
 

	
 

	
A.

	
The persons eligible to participate in the Plan are as follows:

	
 

	
 

	
 

	
 

	
 

	
1.

	
officers and other employees of the Corporation (or any Parent or Subsidiary) who render services to the Corporation (or any Parent or Subsidiary);

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
2.

	
non-employee members of the Board or the board of directors of any Parent or Subsidiary; and

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
3.

	
those consultants or other independent contractors who provide valuable services to the Corporation (or any Parent or Subsidiary).

	
 

	
 

	
 

	
 

	
 

	
 

	
B.

	
The Plan Administrator shall have full authority to determine, with respect to the option grants made under the Plan, which eligible individuals are to receive option grants, the number of shares to be covered by each such
grant, the status of the granted option as either an incentive stock option (“Incentive Option”) which satisfies the requirements of Code Section 422 or a non-statutory option not intended to meet such requirements, the time or times at which each
granted

4

	
 

	
 

	
option is to become exercisable and the maximum term for which the option may remain outstanding.

	
 

	
 

	
 

	
V.

	
STOCK SUBJECT TO THE PLAN

	
 

	
 

	
 

	
 

	
A.

	
Shares of Common Stock shall be available for issuance under the Plan and shall be drawn from either the Corporation’s authorized but unissued shares of Common Stock or from reacquired shares of Common Stock, including
shares repurchased by the Corporation on the open market.  Subject to adjustment as provided in this Section V, the aggregate number of shares which may be issued pursuant to the Plan shall be equal to (a) the number of shares of Common Stock remaining available
for issuance under the Predecessor Plan immediately prior to the termination of the Predecessor Plan, plus (b) any shares of Common Stock covered by stock options granted under the Predecessor Plan that expire or otherwise terminate without being exercised following
the termination of the Predecessor Plan, plus (c) 1,750,000 shares of Common Stock.  To the extent one or more outstanding options under the Predecessor Plan which have been incorporated into this Plan are subsequently exercised, the number of shares issued with
respect to each such option shall reduce, on a share-for-share basis, the number of shares available for issuance under this Plan.

	
 

	
 

	
 

	
 

	
B.

	
In no event may the maximum number of shares of Common Stock for which any one individual participating in the Plan may be granted stock options and separately exercisable stock appreciation rights exceed 500,000 shares in the
aggregate in any calendar year.  Such limitation shall be subject to periodic adjustment in accordance with the provisions of this Section V.

	
 

	
 

	
 

	
 

	
C.

	
Should one or more outstanding options under this Plan (including outstanding options under the Predecessor Plan incorporated into this Plan) expire or terminate for any reason prior to exercise in full, then the shares
subject to the portion of each option not so exercised shall be available for subsequent option grants under the Plan.  Any unvested shares issued under the Plan and subsequently repurchased by the Corporation, at the option exercise price paid per share,
pursuant to the Corporation’s repurchase rights under the Plan shall be added back to the number of shares of Common Stock reserved for issuance under the Plan and shall accordingly be available for reissuance through one or more subsequent non- statutory
option grants (but not Incentive Option grants) under the Plan.  However, any shares subject to any option or portion thereof surrendered in accordance with Section IX shall reduce on a share-for-share basis the number of shares of Common Stock available for
subsequent option grants under the Plan.  In addition, should the option price of an outstanding option under the Plan (including any option incorporated from the Predecessor Plan) be paid with shares of Common Stock or should shares of Common Stock otherwise
issuable under the Plan be withheld by the Corporation in satisfaction of the withholding taxes incurred in connection with the exercise of an outstanding stock option under the Plan, then the number of shares of Common Stock available for issuance under the Plan
shall be reduced by the gross number of shares for which the option is exercised or which vest under the stock issuance, and not by the net number of shares of Common Stock actually issued.

	
 

	
 

	
 

	
 

	
D.

	
Should any change be made to the Common Stock issuable under the Plan by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding Common
Stock as a class without the Corporation’s receipt of consideration, then appropriate adjustments shall be made to (i) the maximum number and/or class of securities issuable under the Plan, (ii) the maximum number and/or class of securities for which any one
individual participating in the Plan may be granted options and separately exercisable stock appreciation rights, (iii) the number and/or class of securities and price per share in effect under each option or stock appreciation right outstanding under the Plan and
(iv) the number and/or class of securities and price per share in effect under each outstanding option or stock appreciation right incorporated into this Plan from the Predecessor Plan.  Such adjustments to the outstanding options and stock appreciation right
are to be effected in a manner which shall

5

	
 

	
 

	
preclude the enlargement or dilution of rights and benefits under such options or rights.  The adjustments determined by the Plan Administrator shall be final, binding and conclusive.

	
 

	
 

	
 

	
VI.

	
TERMS AND CONDITIONS OF OPTIONS

	
 

	
 

	
 

	
 

	
Options granted pursuant to the Plan shall be authorized by action of the Plan Administrator and may, at the Plan Administrator’s discretion, be either Incentive Options or non-statutory options.  Individuals who
are not Employees of the Corporation or any Parent or Subsidiary may only be granted non-statutory options.  Each granted option shall be evidenced by one or more instruments in the form approved by the Plan Administrator; provided, however, that each
such instrument shall comply with the terms and conditions specified below.  Each instrument evidencing an Incentive Option shall, in addition, be subject to the applicable provisions of Section VII.

	
 

	
 

	
 

	
 

	
A.

	
Option Price.

	
 

	
 

	
 

	
 

	
 

	
1.

	
Subject to any limitations set forth in Section VII(B), the per share exercise price shall be fixed by the Plan Administrator, except that: (i) in no event shall the per share exercise price be less than seventy-five percent
(75%) of the Fair Market Value per share of Common Stock on the gate of grant, and (ii) in no event shall the per share exercise price in the case of an Incentive Option or an option intended to qualify as performance-based compensation under Section 162(m) of the
Code be less than one hundred percent (100%) of the Fair Market Value per share of such Common Stock on the date of grant.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
2.

	
The exercise price shall become immediately due upon exercise of the option and, subject to the provisions of Section X and the instrument evidencing the grant, shall be payable in one of the following alternative forms
specified below:

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
a..

	
full payment in shares of Common Stock held for the requisite period necessary to avoid a charge to the Corporation’s earnings for financial reporting purposes and valued at Fair Market Value on the Exercise Date (as
such term is defined below);

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
b.

	
full payment in cash or check drawn to the Corporation’s order;

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
c.

	
full payment in a combination of shares of Common Stock held for the requisite period necessary to avoid a charge to the Corporation’s earnings for financial reporting purposes and valued at Fair Market Value on the
Exercise Date and cash or check drawn to the Corporation’s order; or

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
d.

	
full payment through a broker-dealer sale and remittance procedure pursuant to which the Optionee shall provide irrevocable instructions (I) to a Corporation-designated brokerage firm to effect the immediate sale of the
purchased shares and remit to the Corporation, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate exercise price payable for the purchased shares plus the applicable Federal and State income and employment taxes
required to be withheld by the Corporation in connection with such purchase in order to avoid a charge to the Corporation’s earnings for financial reporting purposes, and (II) to the Corporation to deliver the certificates for the purchased shares directly to
such brokerage firm in order to complete the sale transaction.

	
 

	
 

	
 

	
 

	
 

	
 

	
For purposes of this subparagraph (2), the Exercise Date shall be the date on which written notice of the option exercise is delivered to the Corporation.  Except to the extent the sale and remittance procedure
is

6

	
 

	
utilized in connection with the exercise of the option, payment of the option price for the purchased shares must accompany such notice.

	
 

	
 

	
 

	
B.

	
Term and Exercise of Options.  Each option granted under the Plan shall be exercisable at such time or times and during such period as is determined by the Plan Administrator and set forth in the instrument
evidencing the grant.  No such option, however, shall have a maximum term in excess of ten (10) years from the grant date.

	
 

	
 

	
 

	
 

	
C.

	
Termination of Service.

	
 

	
 

	
 

	
 

	
 

	
1

	
The following provisions shall govern the exercise period applicable to any outstanding options held by the Optionee at the time of cessation of Service or death.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
a.

	
Subject to section VI(C)(1)(e) below, should an Optionee cease Service for any reason (including death or Permanent Disability) while holding one or more outstanding options under this Plan, then none of those options shall
(except to the extent otherwise provided pursuant to subparagraph C(3) below) remain exercisable for more than a thirty-six (36)-month period (or such shorter period determined by the Plan Administrator and set forth in the instrument evidencing the grant) measured
from the date of such cessation of Service.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
b.

	
Any option held by the Optionee under this Plan and exercisable in whole or in part on the date of his or her death may be subsequently exercised by the personal representative of the Optionee’s estate or by the person
or persons to whom the option is transferred pursuant to the Optionee’s will or in accordance with the laws of descent and distribution.  Such exercise, however, must occur prior to the earlier of (i) the third anniversary of the date of the
Optionee’s death (or such shorter period determined by the Plan Administrator and set forth in the instrument evidencing the grant) or (ii) the specified expiration date of the option term.  Upon the occurrence of the earlier event, the option shall
terminate and cease to be outstanding.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
c.

	
During the applicable post-Service exercise period, the option may not be exercised in the aggregate for more than the number of shares (if any) in which the Optionee is vested at the time of cessation of Service.  Upon
the expiration of the limited post-Service exercise period or (if earlier) upon the specified expiration date of the option term, each such option shall terminate and cease to be outstanding with respect to any vested shares for which it has not otherwise been
exercised.  However, each outstanding option shall immediately terminate and cease to be outstanding, at the time of the Optionee’s cessation of Service, with respect to any shares for which it is not otherwise at that time exercisable or in which Optionee
is not otherwise at that time vested.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
d.

	
Under no circumstances, however, shall any such option be exercisable after the specified expiration date of the option term.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
f.

	
Should (i) the Optionee’s Service be terminated for Cause, or (ii) the Optionee make any unauthorized use or disclosure of confidential information or trade secrets of the Corporation or any Parent or Subsidiary, then in
any such event all outstanding options held by the Optionee under this Plan shall terminate immediately and cease to be outstanding.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
2.

	
The Plan Administrator shall have complete discretion, exercisable either at the time the option is granted or at any time while the option remains outstanding, to permit one or more options held by the Optionee under this
Plan to be exercised, during the limited post-Service exercise period applicable under subparagraph (1) above, not only with

7

	
 

	
 

	
 

	
respect to the number of vested shares of Common Stock for which each such option is exercisable at the time of the Optionee’s cessation of Service but also with respect to one or more subsequent installments of shares
for which the option would otherwise have become exercisable had such cessation of Service not occurred.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
3.

	
The Plan Administrator shall also have full power and authority to extend the period of time for which the option is to remain exercisable following the Optionee’s cessation of Service or death from the limited period in
effect under subparagraph (1) above to such greater period of time as the Plan Administrator shall deem appropriate.  In no event, however, shall such option be exercisable after the specified expiration date of the option term.

	
 

	
 

	
 

	
 

	
 

	
 

	
D.

	
Stockholder Rights.  An Optionee shall have no stockholder rights with respect to any shares covered by the option until such individual shall have exercised the option and paid the option price for the purchased
shares.

	
 

	
 

	
 

	
 

	
 

	
 

	
E.

	
Repurchase Rights.  The shares of Common Stock acquired upon the exercise of any option granted under this Plan may be subject to repurchase by the Corporation in accordance with the following
provisions:

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
a.

	
The Plan Administrator shall have the discretion to authorize the issuance of unvested shares of Common Stock under this Plan.  Should the Optionee cease Service while holding such unvested shares, the Corporation shall
have the right to repurchase any or all of those unvested shares at the option price paid per share.  The terms and conditions upon which such repurchase right shall be exercisable (including the period and procedure for exercise and the appropriate vesting
schedule for the purchased shares) shall be established by the Plan Administrator and set forth in the instrument evidencing such repurchase right.

	
 

	
 

	
 

	
 

	
 

	
 

	

 

	
 

	
b.

	
All of the Corporation’s outstanding repurchase rights under this Plan shall automatically terminate, and all shares subject to such terminated rights shall immediately vest in full, upon the occurrence of a Corporate
Transaction, except to the extent: (i) any such repurchase right is expressly assigned to the successor corporation (or Parent thereof) in connection with the Corporate Transaction or (ii) such accelerated vesting is precluded by other limitations imposed by the Plan
Administrator at the time the repurchase right is issued.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
c.

	
The Plan Administrator shall have the discretionary authority, exercisable either before or after the Optionee’s cessation of Service, to cancel the Corporation’s outstanding repurchase rights with respect to one
or more shares purchased or purchasable by the Optionee under this Plan and thereby accelerate the vesting of such shares in whole or in part at any time.

	
 

	
 

	
 

	
 

	
 

	
 

	
F.

	
Limited Transferability of Options.  During the lifetime of the Optionee, Incentive Options shall be exercisable only by the Optionee and shall not be assignable or transferable other than by will or by the laws of
descent and distribution following the Optionee’s death.  However, non-statutory options may, in connection with the Optionee’s estate plan, be assigned in whole or in part during the Optionee’s lifetime to one or more members of the
Optionee’s immediate family or to a trust established exclusively for one or more such family members.  The assigned portion may only be exercised by the person or persons who acquire a proprietary interest in the option pursuant to the assignment. 
The terms applicable to the assigned portion shall be the same as those in effect for the option immediately prior to such assignment and shall be set forth in such documents issued to the assignee as the Plan Administrator may deem appropriate.  Should the
Optionee die while holding a non-statutory option, that option shall be transferred in accordance with the Optionee’s will or by the laws of descent and distribution.

8

	
VII

	
INCENTIVE OPTIONS

	
 

	
 

	
 

	
 

	
 

	
 

	
The terms and conditions specified below shall be applicable to all Incentive Options granted under this Plan.  Incentive Options may only be granted to individuals who are Employees of the Corporation.  Options
which are specifically designated as “non-statutory” options when issued under the Plan shall not be subject to such terms and conditions.

	
 

	
 

	
 

	
 

	
 

	
 

	
A.

	
Dollar Limitation.  The aggregate Fair Market Value (determined as of the respective date or dates of grant) of the Common Stock for which one or more options granted to any Employee, under this Plan (or any other
option plan of the Corporation or any Parent or Subsidiary) may for the first time become exercisable as Incentive Options under the Federal tax laws during any one calendar year shall not exceed the sum of One Hundred Thousand Dollars ($100,000).  To the extent
the Employee holds two (2) or more such options which become exercisable for the first time in the same calendar year, the foregoing limitation on the exercisability of such options as Incentive Options under the Federal tax laws shall be applied on the basis of the
order in which such options are granted.  Should the number of shares of Common Stock for which any Incentive Option first become exercisable in any calendar year exceed the applicable One Hundred Thousand Dollar ($100,000) limitation, then that option may
nevertheless be exercised in that calendar year for the excess number of shares as a non-statutory option under the Federal tax laws.

	
 

	
 

	
 

	
 

	
 

	
 

	
B.

	
10% Stockholder.  If any individual to whom an Incentive Option is granted is the owner of stock (as determined under Section 424(d) of the Code) possessing ten percent (10%) or more of the total combined voting
power of all classes of stock of the Corporation or any Parent or Subsidiary, then the option price per share shall not be less than one hundred and ten percent (110%) of the Fair Market Value per share of Common Stock on the grant date, and the option term shall not
exceed five (5) years, measured from the grant date.

	
 

	
 

	
 

	
 

	
 

	
 

	
Except as modified by the preceding provisions of this Section VII, the provisions of the Plan shall apply to all Incentive Options granted hereunder.

	
 

	
 

	
 

	
 

	
 

	
VIII.

	
CORPORATE TRANSACTIONS/CHANGES IN CONTROL

	
 

	
 

	
 

	
 

	
 

	
 

	
A.

	
In the event of any Corporate Transaction, the vesting of each option which is at the time outstanding under this Plan shall automatically accelerate so that each such option shall, immediately prior to the specified effective
date for the Corporate Transaction, become fully exercisable with respect to the total number of shares of Common Stock at the time subject to such option and may be exercised for all or any portion of such shares as fully vested shares.  However, an outstanding
option under this Plan shall not so accelerate if and to the extent: (i) such option is, in connection with the Corporate Transaction, either to be assumed by the successor corporation or Parent thereof or to be replaced with a comparable option to purchase shares of
the capital stock of the successor corporation or Parent thereof, (ii) such option is to be replaced with a cash incentive program of the successor corporation which preserves the option spread existing at the time of the Corporate Transaction and provides for
subsequent payout in accordance with the same vesting schedule applicable to such option, or (iii) the acceleration of such option is subject to other limitations imposed by the Plan Administrator at the time of the option grant.  The determination of option
comparability under clause (i) above shall be made by the Plan Administrator, and its determination shall be final, binding and conclusive.

	
 

	
 

	
 

	
 

	
 

	
 

	
B.

	
Upon the consummation of the Corporate Transaction, all outstanding options under this Plan shall terminate and cease to be outstanding, except to the extent assumed by the successor corporation or its Parent
company.

9

	
 

	
C.

	
Each outstanding option under this Plan which is assumed in connection with the Corporate Transaction or is otherwise to continue in effect shall be appropriately adjusted, immediately after such Corporate Transaction, to
apply and pertain to the number and class of securities which would have been issued to the option holder, in consummation of such Corporate Transaction, had such person exercised the option immediately prior to such Corporate Transaction.  Appropriate
adjustments shall also be made to the option price payable per share, provided the aggregate option price payable for such securities shall remain the same.  In addition, the class and number of securities available for issuance under the Plan on both an
aggregate and per participant basis following the consummation of the Corporate Transaction shall be appropriately adjusted.

	
 

	
 

	
 

	
 

	
 

	
 

	
D.

	
The Plan Administrator shall have full power and authority to grant options under the Plan which will automatically accelerate in whole or in part should the Optionee’s Service subsequently terminate within a designated
period following the effective date of any Corporate Transaction in which those options are assumed or replaced and do not otherwise accelerate.  In addition, the Plan Administrator may provide that one or more of the Corporation’s outstanding repurchase
rights with respect to shares held by the Optionee at the time of such termination of Service shall immediately terminate in whole or in part, and the shares subject to those terminated rights shall accordingly vest.

	
 

	
 

	
 

	
 

	
 

	
 

	
E.

	
The Plan Administrator shall have full power and authority to grant options under the Plan which will automatically accelerate in whole or in part in the event that a Change in Control occurs or in the event that the
Optionee’s Service terminates within a designated period following the effective date of a Change in Control.  In addition, the Plan Administrator may provide that one or more of the Corporation’s outstanding repurchase rights with respect to shares
held by the Optionee at the time of such Change in Control or termination of Service shall immediately terminate in whole or in part, and the shares subject to those terminated rights shall accordingly vest.

	
 

	
 

	
 

	
 

	
 

	
 

	
F.

	
Any options accelerated in connection with the Change in Control shall remain fully exercisable until the expiration or sooner termination of the option term.

	
 

	
 

	
 

	
 

	
 

	
 

	
G.

	
The grant of options under this Plan shall in no way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or
sell or transfer all or any part of its business or assets.

	
 

	
 

	
 

	
 

	
 

	
 

	
H.

	
Any Incentive Options accelerated under this Section VIII in connection with a Corporate Transaction or Change in Control shall remain exercisable as incentive stock options under the Federal tax laws only to the extent the
applicable dollar limitation of Section VII is not exceeded.  To the extent such dollar limitation is exceeded, the accelerated option shall be exercisable as a non-statutory option under the Federal tax laws.

	
 

	
 

	
 

	
 

	
 

	
IX.

	
STOCK APPRECIATION RIGHTS

	
 

	
 

	
 

	
 

	
 

	
 

	
A.

	
Provided and only if the Plan Administrator determines in its discretion to implement the stock appreciation right provisions of this Section IX, one or more Optionees may be granted the right, exercisable upon such terms and
conditions as the Plan Administrator may establish, to surrender all or part of an unexercised option under this Plan in exchange for a distribution from the Corporation in an amount equal to the excess of (i) the Fair Market Value (on the option surrender date) of
the shares of Common Stock in which the Optionee is at the time vested under the surrendered option (or surrendered portion thereof) over (ii) the aggregate option price payable for such vested shares.

	
 

	
 

	
 

	
 

	
 

	
 

	
B.

	
No surrender of an option shall be effective hereunder unless it is approved by the Plan Administrator.  If the surrender is so approved, then the distribution to which the Optionee shall accordingly become entitled under
this Section IX may be made in shares of Common Stock

10

	
 

	
 

	
valued at Fair Market Value on the option surrender date, in cash, or partly in shares and partly in cash, as the Plan Administrator deems appropriate.

	
 

	
 

	
 

	
 

	
 

	
 

	
C.

	
If the surrender of an option is rejected by the Plan Administrator, then the Optionee shall retain whatever rights the Optionee had under the surrendered option (or surrendered portion thereof) on the option surrender date
and may exercise such rights at any time prior to the later of (i) five (5) business days after the receipt of the rejection notice or (ii) the last day on which the option is otherwise exercisable in accordance with the terms of the instrument evidencing such
option, but in no event may such rights be exercised more than ten (10) years after the date of the option grant.

	
 

	
 

	
 

	
 

	
 

	
 

	
D.

	
One or more officers of the Corporation subject to the short-swing profit restrictions of the Federal securities laws may, in the Plan Administrator’s sole discretion, be granted limited stock appreciation rights in
tandem with their outstanding options under the Plan.  Upon the occurrence of a Hostile Take-Over, the officer will have a thirty (30)-day period in which he or she may surrender any outstanding options with such a limited stock appreciation right to the
Corporation, to the extent such options are at the time exercisable for fully-vested shares of Common Stock.  The officer shall in return be entitled to a cash distribution from the Corporation in an amount equal to the excess of (i) the Take-Over price of the
vested shares of Common Stock at the time subject to each surrendered option over (ii) the aggregate option price payable for such vested shares.  The cash distribution payable upon such option surrender shall be made within five (5) days following the date the
option is surrendered to the Corporation.  The Plan Administrator shall pre- approve, at the time the limited stock appreciation right is granted, the subsequent exercise of that right in accordance with the terms of the grant and the provisions of this Section
IX(D).  No additional approval of the Plan Administrator or the Board shall be required at the time of the actual option surrender and cash distribution.  Any unsurrendered portion of the option shall continue to remain outstanding and become exercisable in
accordance with the terms of the instrument evidencing such grant.

	
 

	
 

	
 

	
 

	
 

	
 

	
E.

	
The shares of Common Stock subject to any option surrendered for an appreciation distribution pursuant to this Section IX shall not be available for subsequent option grant under the Plan.

	
 

	
 

	
 

	
 

	
 

	
X.

	
LOANS OR INSTALLMENT PAYMENTS

	
 

	
 

	
 

	
 

	
 

	
 

	
A.

	
The Plan Administrator may, in its discretion, assist any Optionee (including an Optionee who is an officer of the Corporation) in the exercise of one or more options granted to such Optionee under the Plan, including the
satisfaction of any Federal and state income and employment tax obligations arising therefrom, by (i) authorizing the extension of a loan from the Corporation to such Optionee or (ii) permitting the Optionee to pay the option price for the purchased Common Stock in
installments over a period of years, provided, however, that the Optionee must pay in cash or cash equivalents, immediately upon exercise, that amount equal to the total par value for the aggregate shares of Common Stock purchased.  The terms of
any loan or installment method of payment (including the interest rate and terms of repayment) shall be upon such terms as the Plan Administrator specifies in the applicable option agreement or otherwise deems appropriate under the circumstances, and which terms
shall be in accordance with any applicable rules and regulations established by the United States Federal Reserve Board.  Loans or installment payments may be authorized with or without security or collateral.  However, the maximum credit available to the
Optionee may not exceed the option price of the acquired shares plus any Federal and state income and employment tax liability incurred by the Optionee in connection with the acquisition of such shares.

	
 

	
 

	
 

	
 

	
 

	
 

	
B.

	
The Plan Administrator may, in its absolute discretion, determine that one or more loans extended under this financial assistance program shall be subject to forgiveness by the Corporation in whole or in part upon such terms
and conditions as the Plan Administrator may deem appropriate.

11

	
XI.

	
AMENDMENT OF THE PLAN AND AWARDS

	
 

	
 

	
 

	
 

	
 

	
 

	
The Board has complete and exclusive power and authority to amend or modify the Plan (or any component thereof) in any or all respects whatsoever.  However, no such amendment or modification shall adversely affect rights
and obligations with respect to options or stock appreciation rights at the time outstanding under the Plan, unless the Optionee consents to such amendment.  In addition, the exercise price of an outstanding option shall not be decreased after issuance without
stockholder approval.  Certain amendments may require stockholder approval pursuant to applicable laws or regulations.

	
 

	
 

	
 

	
 

	
 

	
XII.

	
TAX WITHHOLDING

	
 

	
 

	
 

	
 

	
 

	
 

	
A.

	
The Corporation’s obligation to deliver shares of Common Stock upon the exercise of stock options for such shares or the vesting of such shares under the Plan shall be subject to the satisfaction of all applicable
Federal, state and local income and employment tax withholding requirements.

	
 

	
 

	
 

	
 

	
 

	
 

	
B.

	
The Plan Administrator may, in its discretion and in accordance with the provisions of this Section XII and such supplemental rules as the Plan Administrator may from time to time adopt, provide any or all holders of
non-statutory options or unvested shares under the Plan with the right to use shares of the Corporation’s Common Stock in satisfaction of all or part of the Federal, state and local income and employment tax liabilities incurred by such holders in connection
with the exercise of their options or the vesting of their shares (the “Taxes”).  Such right may be provided to any such holder in either or both of the following formats:

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
1.

	
Stock Withholding: The holder of the non- statutory option or unvested shares may be provided with the election to have the Corporation withhold, from the shares of Common Stock otherwise issuable upon the exercise of
such non-statutory option or the vesting of such shares, a portion of those shares with an aggregate Fair Market Value equal to the percentage of the applicable Taxes (not to exceed one hundred percent (100%)) designated by the holder in order to avoid a charge to
the Corporation’s earnings for financial reporting purposes.

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
2.

	
Stock Delivery: The Plan Administrator may, in its discretion, provide the holder of the non-statutory option or unvested shares purchased thereunder with the election to deliver to the Corporation, at the time the
non-statutory option is exercised or the shares vest, one or more shares of Common Stock previously acquired by such individual (other than in connection with the option exercise or share vesting triggering the Taxes) with an aggregate Fair Market Value equal to the
percentage of the Taxes incurred in connection with such option exercise or share vesting (not to exceed one hundred percent (100%)) designated by the holder in order to avoid a charge to the Corporation’s earnings for financial reporting purposes.

	
 

	
 

	
 

	
 

	
 

	
XIII.

	
EFFECTIVE DATE AND TERM OF PLAN

	
 

	
 

	
 

	
 

	
 

	
 

	
A.

	
This Plan is effective as of the Effective Date, subject to stockholder approval.

	
 

	
 

	
 

	
 

	
 

	
 

	
B.

	
Each option issued and outstanding under the Predecessor Plan immediately prior to the termination of the Predecessor Plan shall be incorporated into this Plan and treated as an outstanding option under this Plan, but each
such option shall continue to be governed solely by the terms and conditions of the instrument evidencing such grant, and nothing in this Plan shall be deemed to affect or otherwise modify the rights or obligations of the holders of such options with respect to their
acquisition of shares of Common Stock thereunder.

12

	
 

	
C.

	
The Plan shall terminate upon the earlier of (i) March 6, 2012, (ii) the date on which all shares available for issuance under the Plan shall have been issued as vested shares or cancelled pursuant to the exercise, surrender
or cash-out of the options granted under the Plan, or (iii) such earlier date as determined by the Board.  Upon such plan termination, all outstanding option grants and stock appreciation rights shall continue to have force and effect in accordance with the
provisions of the instruments evidencing such grants.

	
 

	
 

	
 

	
 

	
 

	
XIV.

	
USE OF PROCEEDS

	
 

	
 

	
 

	
 

	
 

	
 

	
Any cash proceeds received by the Corporation from the sale of shares pursuant to option grants under the Plan shall be used for general corporate purposes.

	
 

	
 

	
 

	
 

	
 

	
XV.

	
REGULATORY APPROVALS

	
 

	
 

	
 

	
 

	
 

	
 

	
A.

	
The implementation of the Plan, the granting of any stock option or stock appreciation right under the Plan and the issuance of Common Stock upon the exercise of the stock options or stock appreciation rights granted hereunder
shall be subject to the Corporation’s procurement of all approvals and permits required by regulatory authorities having jurisdiction over the Plan, the stock options and stock appreciation rights granted under it, and the Common Stock issued pursuant to
it.

	
 

	
 

	
 

	
 

	
 

	
 

	
B.

	
No shares of Common Stock or other assets shall be issued or delivered under this Plan unless and until there shall have been compliance with all applicable requirements of Federal and State securities laws, including the
filing and effectiveness of the Form S-8 registration statement for the shares of Common Stock issuable under the Plan, and all applicable listing requirements of any securities exchange on which stock of the same class is then listed.

	
 

	
 

	
 

	
 

	
 

	
XVI.

	
NO EMPLOYMENT/SERVICE RIGHTS

	
 

	
 

	
 

	
Neither the action of the Corporation in establishing the Plan, nor any action taken by the Plan Administrator hereunder, nor any provision of the Plan shall be construed so as to grant any individual the right to remain in
the employ or service of the Corporation (or any Parent or Subsidiary) for any period of specific duration, and the Corporation (or any Parent or Subsidiary) retaining the services of such individual) may terminate such individual’s employment or service at any
time and for any reason, with or without cause.

	
 

	
 

	
 

	
 

	
 

	
XVII.

	
NON-U.S. EMPLOYEES

	
 

	
 

	
 

	
Notwithstanding anything in the Plan to the contrary, with respect to any employee who is a resident outside the United States, the Board may, in its sole discretion, amend the terms of the Plan in order to conform such terms
with the requirements of local law or to meet the objectives of the Plan; provided, however, that this Section XVII shall not authorize the Board to amend the provisions of Section V(A) hereof relating to the number of shares authorized under the Plan.  The
Board may, where appropriate, establish one or more sub-plans for this purpose.

	
 

	
 

	
 

	
 

	
 

	
XVIII.

	
MISCELLANEOUS PROVISIONS

	
 

	
 

	
 

	
 

	
 

	
 

	
A.

	
Except to the extent otherwise expressly provided in the Plan, the right to acquire Common Stock or other assets under the Plan may not be assigned, encumbered or otherwise transferred by any Optionee.

13

	
 

	
B.

	
The provisions of the Plan relating to the exercise of options and the vesting of shares shall be governed by the laws of the State of Delaware without resort to that State’s conflict-of-laws rules.

	
 

	
 

	
 

	
 

	
 

	
 

	
C.

	
The provisions of the Plan shall inure to the benefit of, and be binding upon, the Corporation and its successors or assigns, whether by Corporate Transaction or otherwise, and the Optionees, the legal representatives of their
respective estates, their respective heirs or legatees and their permitted assignees.

	
 

	
 

	
 

	
 

	
 

14OPTION AGREEMENT

Redacted portions have been replaced with [**].  The redacted material is subject to a request for confidential treatment and has been filed separately with the Securities and Exchange Commission.

EXHIBIT 10.17

OPTION AGREEMENT

          This Option Agreement (this “Agreement”) is entered into as of the 8th day of November, 2002 among SangStat Medical
Corporation, a Delaware corporation with its principal place of business at 6300 Dumbarton Circle, Fremont, California 94555 (“SMC”), Research Corporation Technologies, Inc., a Delaware not-for-profit corporation with its
principal place of business at 101 N. Wilmot Road, Suite 600, Tucson, Arizona 85711 (“RCT”) and Therapeutic Human Polyclonals, Inc., a California corporation, with its principal place of business at 101 N. Wilmot Road, Suite
600, Tucson, Arizona 85711 (the “Company”).  SMC and RCT are sometimes hereinafter collectively referred to as the “Investors”.

RECITALS

          A.          SMC, RCT and the Company concurrently herewith are entering into that certain Series A-2 and
Series B Preferred Stock Purchase Agreement dated of even date herewith (the “Stock Purchase Agreement”) pursuant to which, among other things, SMC and RCT shall purchase shares of the Series A-2 Preferred Stock of the Company (the
“Series A-2 Shares”) and, upon the achievement of certain future events as described in the Stock Purchase Agreement, SMC and RCT have agreed to purchase shares of the Series B Preferred Stock of the Company (the “Series B
Shares”).

          B.          As an inducement to SMC and RCT to enter into the Stock Purchase Agreement and to consummate the
transactions contemplated thereby, the Company wishes to grant (i) to SMC and RCT, collectively, an option to purchase the Series B Shares if those events which would give rise to an obligation, under the Stock Purchase Agreement, to purchase the Series B Shares are
not achieved, and (ii) to grant to SMC an exclusive, irrevocable option to acquire shares of the Series C Preferred Stock of the Company (the “Series C Shares”) upon the occurrence of certain events as described herein.  Terms used
herein with initial capital letters, but not otherwise defined herein, shall have the meanings given such terms in the Stock Purchase Agreement.

AGREEMENT

          In consideration of the foregoing premises and the mutual covenants and conditions set forth below, and for other good and valuable consideration, the receipt of
which is hereby acknowledged, the parties to this Agreement hereby agree as follows:

          1.          Option to Purchase Series B Shares.

                        1.1          Option to
Purchase.  The Company hereby grants to SMC and RCT an option (the “Primary G2A Option”) to purchase certain Series B Shares (as hereinafter described), which option may only be exercised if the Company has determined that it has
not achieved the G2A Milestone on or before the first anniversary of the First Closing, and which option must be exercised by both SMC and RCT in the manner described, and subject to the terms and conditions set forth, below.  In the event that the Primary G2A
Option is not exercisable for the reason that RCT has elected not to exercise the Primary G2A Option, then conditioned upon the occurrence of that event, the Company hereby grants to SMC, individually,

1

an option (the “Secondary G2A Option”) to purchase certain Series B Shares in the manner described, and subject to the terms and conditions set forth, below.  Only the Primary G2A Option or the
Secondary G2A Option may be elected by the Investors, but not both.  References herein to the “G2A Option” shall mean and refer to either the Primary G2A Option or the Secondary G2A Option, as applicable, if one has been validly
exercised.

                        1.2          Purchase
Price and Number of Shares.  The purchase price for any Series B Shares to be acquired by the Investors pursuant to the G2A Option shall be Four and 35/100 Dollars ($4.35) per share.  If both SMC and RCT elect to exercise the Primary G2A Option,
SMC’s election shall be effective for the purchase of Six Hundred Seventy-One Thousand Two Hundred Sixty-Four (671,264) Series B Shares, for a total purchase price payable by SMC in the amount of $2,919,998.40 and RCT’s election shall be effective for the
purchase of Three Hundred Seventy-Seven Thousand Five Hundred Eighty-Six (377,586) Series B Shares, for a total purchase price of $1,642,499.10.  In the event that RCT elects not to exercise the Primary G2A Option, then, pursuant to the Secondary G2A Option, SMC
shall have the right to exercise the Secondary G2A Option and purchase a number of Series B Shares to be designated by SMC; provided, however, that in no event shall the number of Series B Shares to be purchased by SMC pursuant to the Secondary G2A Option be
less than Five Hundred Seventy-Four Thousand Seven Hundred Thirteen (574,713) shares, for a total purchase price of $2,500,001.50, nor greater than One Million One Hundred Forty-Nine Thousand Four Hundred Twenty-Five (1,149,425) shares, for a total purchase price of
$4,999,998.70.

                        1.3          Conversion of G2A Option to Mandatory
Purchase.  If, at any time within sixty (60) days following the delivery of the G2A Progress Report (as defined in Section 2.1 hereof) and prior to delivery of any notice of exercise by an Investor, as described in Section 2 hereof, the Company reasonably
determines that it has achieved the G2A Milestone, the Company shall have the right to deliver to the Investors (i) the G2A Milestone Report, (ii) the Interim Financial Report, and (iii) the Certification Concerning the Absence of Negative Developments (each as
defined in Section 6.1 of the Stock Purchase Agreement), in which event both the Primary G2A Option and the Secondary G2A Option shall terminate and expire.  Upon delivery of the G2A Milestone Report to the Investors pursuant to this Section 1.3, the rights and
obligations of the parties with respect to the purchase and sale of the Series B Shares shall be determined pursuant to Section 6 of the Stock Purchase Agreement, in the same manner as if the G2A Milestone had been achieved, and the G2A Milestone Report had been
delivered (and the G2A Milestone shall be deemed to have been achieved, and the G2A Milestone Report shall be deemed to have been delivered), prior to the first anniversary of the First Closing.

          2.          Manner of Exercise of G2A Option.

                        2.1          Notice of Exercise.

                                        (a)          If
the Company has not achieved the G2A Milestone on or before the first anniversary of the First Closing, the Company will deliver to the Investors a report (i) that documents the scientific achievements made by the Company subsequent to the First Closing, (ii) an
updated Disclosure Schedule, and (iii) updated Company Financial Statements (such report being referred to herein as the “G2A Progress Report”).  On or before 5:00 p.m. local time in Tucson, Arizona on the twentieth (20th)
day following the date of delivery of the

2

G2A Progress Report (or, if such day is not a business day, 5:00 p.m. local time in Tucson, Arizona, on the next business day) (such date being referred herein as the “First G2A Required Exercise
Date”, RCT shall deliver written notice to the Company advising the Company whether RCT intends to exercise the Primary G2A Option.  If RCT notifies the Company that it has elected to exercise the Primary G2A Option, such written notice of election
shall be referred to herein as the “RCT Notice of Exercise”.  In the event that RCT has not delivered to the Company the RCT Notice of Exercise prior to the First G2A Required Exercise Date, then RCT shall be deemed to have elected not
to exercise the Primary G2A Option.  Promptly upon receipt of a RCT Notice of Exercise, or alternatively on receipt of notification from RCT that it does not intend to exercise the Primary G2A Option or on the business day following the First G2A Required
Exercise Date, the Company shall promptly deliver a copy of any RCT Notice of Exercise to SMC or shall otherwise advise SMC in writing that RCT’s right to exercise the Primary G2A Option has been declined or otherwise lapsed. 

                                        
(b)          If RCT exercises the Primary G2A Option, then SMC shall have the right to exercise the Primary G2A Option and the Secondary G2A Option shall never arise.  On or before 5:00 p.m. local time in Tucson,
Arizona, on the thirtieth (30th) day following the date of delivery of the G2A Progress Report (or if such day is not a business day, 5:00 p.m. local time in Tucson, Arizona on the next business day) (such date being referred to herein as the
“Final G2A Required Exercise Date”), SMC shall deliver to the Company written notice stating whether SMC elects to exercise the Primary G2A Option.   If SMC notifies the Company that it has elected to exercise the Primary G2A Option,
such written notice of election shall be referred to herein as the “SMC Primary Notice of Exercise”.  Following receipt of the SMC Primary Notice of Exercise, the Company shall promptly provide a copy to RCT.  In the event SMC
notifies the Company that it has elected not to exercise the Primary G2A Option, or if no SMC Primary Notice of Exercise is received by the Company on or before the Final G2A Required Exercise Date, then the Primary G2A Option shall terminate and expire, and the
Company shall promptly provide notice to RCT to that effect.

                                        
(c)          If RCT either elects not to exercise the Primary G2A Option or allows its right to exercise the Primary G2A Option to lapse, then the Primary G2A Option shall terminate and expire, and SMC shall have the
option to exercise the Secondary G2A Option.  In that event, on or before the Final G2A Required Exercise Date, SMC shall deliver to the Company written notice of its election to exercise the Secondary G2A Option (the “SMC Secondary Notice of
Exercise”).  The SMC Secondary Notice of Exercise shall specify the number of Series B Shares which SMC is electing to purchase pursuant to the Secondary G2A Option (which shall not be less than 574,713, nor more than 1,149,425, of the Series B
Shares, as set forth in Section 1.2 above).  Upon receipt of a SMC Secondary Notice of Exercise, the Company shall promptly deliver a copy thereof to RCT, and in the event the Company receives notice from SMC that SMC has elected not to exercise the Secondary
G2A Option, the Company shall promptly notify RCT to that effect.  In the event the Company has not received the SMC Secondary Notice of Exercise on or before the Final G2A Required Exercise Date, the Secondary G2A Option shall terminate and expire.

3

                        2.2          Timing of
Closing.

                         (a)          In the event that
either (i) both SMC and RCT have elected to exercise the Primary G2A Option or (ii) SMC has elected to exercise the Secondary G2A Option, the applicable Investors who have exercised G2A Option shall have until 5:00 p.m local time in Tucson, Arizona, on the
sixtieth (60th) day following delivery of the G2A Progress Report (or if such day is not a business day, 5:00 p.m. local time in Tucson, Arizona, on the next business day) (such date being referred to herein as the “G2A Option Expiration
Date”) either to (I) complete the Series B Closing (as defined in Section 3.1 below) or (II) provide written notice to the Company (the “Tender Notice”) that such Investor or Investors are ready, willing and able to
complete the Series B Closing pending receipt of closing deliverables from the Company in accordance with the Series B Stock Purchase Agreement, as hereinafter defined.

                         (b)          In the event that
either the Series B Closing has not occurred or a Tender Notice has not been delivered to the Company by the applicable Investors who have exercised the G2A Option on or before the G2A Option Expiration Date, then the Primary G2A Option (with respect only to such
party or parties failing either (i) to cause the Series B Closing to occur or (ii) to timely deliver a Tender Notice) or the Secondary G2A Option, as applicable, will terminate and expire.

                        (c)          If both RCT and SMC
have timely exercised the Primary G2A Option, but RCT either fails to cause the Series B Closing to occur or to timely deliver a Tender Notice, then the Company shall deliver notice of such failure to SMC, and SMC shall thereafter have an additional five (5) day
period in which to exercise the Secondary G2A Option by written notice to the Company (the “Option Extension”).  If SMC so elects to exercise the Secondary G2A Option pursuant to this Section 2.2(c), then SMC shall have until 5:00 p.m.
local time, in Tucson, Arizona on the seventh (7th) day following delivery of the Option Extension notice (or if such day is not a business day, 5:00 p.m. local time in Tucson, Arizona, on the next business day) in order to either complete the Series B
Closing (as defined in Section 3.1 below) or to provide a Tender Notice to the Company.

                        2.3          Right to
Assign.  If RCT elects to exercise the Primary G2A Option, it shall have the same right to assign all or a portion of its right to acquire the Series B Shares to one or more other Persons as is set forth in Section 6.5 of the Stock Purchase Agreement,
subject to the conditions and limitations set forth therein.

          3.          Agreement to Sell and Purchase Series B Shares.

                        3.1          Preparation of
Stock Purchase Agreement.  Promptly following receipt by the Company of (i) both the RCT Notice of Exercise and the SMC Primary Notice of Exercise, or (ii) the SMC Secondary Notice of Exercise, the Company shall cause to be prepared a Series B
Preferred Stock Purchase Agreement, in form and substance substantially identical to the Stock Purchase Agreement (subject to such modifications as are necessary to reflect the specifics of the transaction with respect to the exercise of the G2A Option and events
arising subsequent to the date of the Stock Purchase Agreement, including without limitation the delivery of an updated Disclosure Schedule in connection therewith).  Such agreement shall be referred to herein as the “Series B Stock Purchase
Agreement.”  The issuance and sale of the

4

Series B Shares shall then be consummated pursuant to the terms of the Series B Stock Purchase Agreement, the closing of the issuance of the Series B Shares thereunder to RCT and SMC, pursuant to the Primary G2A Option, or
solely to SMC pursuant to the Secondary G2A Option, as applicable, shall be referred to herein as the “Series B Closing,” and the actual date the Series B Closing takes place shall be referred to herein as “Series B
Closing Date.”

          4.           Option to Purchase Series C Shares.  The Company hereby grants to SMC an exclusive
and irrevocable option (the “F2A Option”) to acquire 2,307,692 shares (but not less than 2,307,692 shares) of the Company’s Series C Preferred Stock (the “Series C Shares”) at a purchase price of Six and 50/100 Dollars
($6.50) per share, on the terms and conditions set forth herein.  The F2A Option shall only be exercisable during the period commencing on the occurrence of (I) the Series B Closing or (II) a G2A Closing, in either case in which SMC participates in accordance
with either this Option Agreement or the Stock Purchase Agreement, and ending on the F2A Option Expiration Date (as hereinafter defined).  Upon the earlier to occur of the date upon which the Company reasonably determines that it has achieved the F2A Milestone,
or the eighteen (18) month anniversary of the Series B Closing, the Company will deliver a written report (which will include the data from the F2A Assays (as defined in the Collaboration Agreement) to the Investors documenting either (i) the achievement of the F2A
Milestone or (ii) the progress made by the Company toward achieving the F2A Milestone (the “F2A Milestone Report”).  Based upon the F2A Milestone Report, SMC shall have the option to be the sole investor and to acquire all of the Series
C Shares described above for a total purchase price of $14,999,998.

          5.          Manner of Exercise of F2A Option.

                        5.1          Notice of
Exercise.  If SMC intends to exercise the F2A Option, it shall deliver to the Company, on or prior to 5:00 p.m. local time in Tucson, Arizona on or before the fifteenth (15th) day following the date of delivery of the F2A Milestone Report (or,
if such day is not a business day, 5:00 p.m. local time in Tucson, Arizona, on the next business day), written notice of its non-binding intent to do so (the “F2A Notice of Exercise”).  Upon receipt of the F2A Notice of Exercise from SMC, the
Company shall promptly deliver a copy thereof to RCT.  In the event the Company receives a notice from SMC that it has elected not to exercise the F2A Option, the Company shall promptly notify RCT to that effect.  The F2A Option shall terminate and expire
on the date which is thirty (30) days after delivery of the F2A Milestone Report to SMC, unless such day is not a business day, in which event the F2A Option shall terminate and expire on the next business day (such date being referred to herein as the “F2A
Option Expiration Date”) unless the purchase and acquisition of the Series C Shares by SMC (herein, the “Series C Closing”) has occurred on or before the F2A Option Expiration Date; provided, however, that: (i) if the Series C
Closing cannot be consummated by reason of any applicable judgment, decree, order, Legal Requirement (including, but not limited to, regulatory approval) or other legal impediment, if SMC elects not to consummate the Series C Closing because one or more of the
Company’s closing deliveries required by the Series C Stock Purchase Agreement (as hereafter defined) has not been delivered, or if the Series C Stock Purchase Agreement has not been negotiated, despite SMC’s good faith effort to do so, then, in each case
(but subject to the last sentence of this Section 5.1), the Series C Closing Date may be extended by SMC to a date not more than fifteen (15) days after the date on which such impediment is removed or becomes inapplicable or such closing deliveries are delivered; and
(ii) if prior notification to or

5

approval of any Governmental Body or shareholder approval is required in connection with the Series C Closing, the Company or SMC, as the case may be, shall promptly cause to be filed, and shall expeditiously process, the
required notice or application for approval or proxy or information statement (and the Company shall reasonably cooperate with SMC in the filing of any such notice or application required to be filed by SMC and the obtaining of any such approval required to be
obtained by SMC), and the Series C Closing Date may (subject to the last sentence of this Section 5.1) be extended by SMC (in the case of shareholder approval) or the Company (in the case of a governmental approval) to a date not more than fifteen (15) days after the
later of (a) the date on which any required notification or waiting period has expired or been validly terminated, or (b) the date on which any required approval has been obtained.  Anything set forth in this Section 5 to the contrary notwithstanding, in no
event shall the F2A Option Expiration Date be extended for a total of more than sixty (60) days beyond the original F2A Option Expiration Date except with the prior written consent of the Company, which consent the Company shall be entitled to withhold in its sole
discretion.

                        5.2          Update to
Disclosure Schedules.  The Company shall, within ten (10) business days after receiving the F2A Notice of Exercise from SMC, prepare and deliver to SMC an updated Disclosure Schedule specifying any change to the Disclosure Schedule resulting from (i) any
event, condition, fact or circumstance that is required to be disclosed pursuant to Section 2 of the Stock Purchase Agreement, or (ii) any event, condition, fact or circumstance that would require such a change assuming the Disclosure Schedule were dated as of
the date of the occurrence, existence or discovery of such event, condition, fact or circumstance.  The date on which the Company actually delivers the updated Disclosure Schedule to SMC shall be referred to as the “F2A Delivery
Date.”  Such updated Disclosure Schedule shall be cumulative, and shall amend and supplement the initial Disclosure Schedule delivered by the Company to the Investors as of the First Closing Date in connection with the Stock Purchase Agreement and
the updated Disclosure Schedule delivered to the Investors as of the Series B Closing Date in connection with the Series B Stock Purchase Agreement.  To the extent requested by SMC, the Company shall cooperate in providing to SMC all information reasonably
requested by SMC so that it can adequately evaluate the disclosures contained on the updated Disclosure Schedule.  SMC may, at any time prior to the Series C Closing hereunder and for any reason or no reason, elect without penalty not to proceed with the
acquisition of the Series C Shares.  In the event either SMC fails to acquire the Series C Shares hereunder, either as a result of the election not to exercise the F2A Option, or pursuant to the right not to proceed with the acquisition of the Series C Shares
set forth above, SMC shall no longer have any rights or obligations with regard to the purchase or sale of additional shares of capital stock of the Company other than the right of first refusal pursuant to the Investor Rights Agreement (the “Right of
First Refusal”) and pursuant to the Restated Articles (as defined in the Stock Purchase Agreement).

                        5.3          Waiver of
Right of First Refusal by RCT.  In the event SMC elects to exercise the F2A Option, RCT (for itself and on behalf of any other Person who becomes a co-investor by purchasing Series B Shares pursuant to an assignment of all or part of RCT’s right to
purchase such shares in accordance with Section 6.5 of the Stock Purchase Agreement) hereby waives (such waiver to be effective solely for the purchase by SMC of the Series C Shares in strict accordance with the F2A Option and all terms and conditions of this
Agreement) the Right of First Refusal running in favor of each such Person, as set forth in Section 4 of the Investor Rights Agreement.  In the event that SMC fails to close its acquisition of the Series C Shares in

6

strict accordance with the F2A Option and the terms and conditions of this Agreement, then the Right of First Refusal in favor of RCT and its permitted assigns shall continue in full force and effect.

          6.          Agreement to Sell and Purchase Series C Shares.

                        6.1          Preparation of Stock Purchase
Agreement.  Promptly following receipt by the Company of the F2A Notice of Exercise, the Company shall cause to be prepared a Series C Preferred Stock Purchase Agreement, in form and substance substantially identical to the Stock Purchase Agreement (subject
to such modifications as are necessary to reflect the specifics of the transaction with respect to the exercise of the F2A Option and events arising subsequent to the date of the Stock Purchase Agreement), which SMC and the Company shall negotiate in good
faith.  Such agreement shall be referred to herein as the “Series C Stock Purchase Agreement.”  The issuance and sale of the Series C Shares shall then be consummated pursuant to the terms of the Series C Stock Purchase Agreement,
the closing of the issuance of the Series C Shares thereunder to SMC shall be referred to herein as the “Series C Closing,” and the actual date the Series C Closing takes place shall be referred to herein as the “Series C Closing
Date.”

                        6.2          Manner of
Payment for Series C Shares.  The Series C Stock Purchase Agreement shall provide that SMC may pay for the Series C Shares with a combination of (i) cash or other immediately available funds and (ii) SMC common stock; provided, however, that SMC shall
be required to pay at least seventy percent (70%) of the purchase price in cash or other immediately available funds.  If SMC elects to pay any portion of the purchase price for the Series C Shares in SMC common stock, such common stock must be registered common
stock freely tradeable on the NASDAQ market either at the time of or following a Series C Closing, and SMC must agree to enter into the price protection mechanism acceptable to the Company.  A price protection mechanism shall be acceptable to the Company if (I)
the Company is assured of realizing net proceeds from the sale of the SMC common stock received by the Company (during the five (5) consecutive trading day period after the time such stock is freely tradable [i.e., without any volume or other restrictions] on the
NASDAQ market) in an amount at least equal to the deemed value of such SMC common stock at the time of the Series C Closing, and (II) the five (5) trading-day period described in the preceding clause (I) shall only commence at such time as SMC has delivered to the
Company written notification, which notification may be delivered concurrently with the delivery to the Company of the SMC common stock constituting a portion of the purchase price for the Series C Shares, that such SMC common stock is, as of the date of such notice,
freely tradable.  Any price protection mechanism will terminate at the close of trading on the fifth (5th) trading day after the time the SMC common stock issued to THP is freely tradable (as described above) on the NASDAQ market.  In the event
that SMC is unable to agree with the Company on an acceptable price protection mechanism, then SMC shall pay the entire purchase price for the Series C Shares in cash or other immediately available funds.  The foregoing notwithstanding, a price protection
mechanism shall not be deemed unacceptable by the Company for the sole reason that such mechanism reserves the right to SMC to receive any net proceeds resulting from the sale of the SMC common stock which would cause total proceeds received by the Company to be in
excess of the amount which would otherwise have been payable to the Company in cash for the Series C Shares.

7

          7.          Use of Proceeds from Sale of Stock.  The Company shall use the proceeds from the sale
of the Series B Shares and the Series C Shares to advance the development of the Company’s platform technology as described in the Business Plan (as amended and attached as an exhibit to the updated Disclosure Schedules), to develop products under the
Collaboration Agreements, and to conduct preclinical and clinical studies for the Company’s antibody products.

          8.          Representations and Warranties of the Company.   The Company hereby represents
and warrants to each of SMC and RCT as follows:

                        8.1          Authority; Binding Nature of
Agreement.  The Company has the absolute and unrestricted right, power and authority to enter into and perform its obligations under this Agreement, and to grant the G2A Option and the F2A Option.  The execution, delivery and performance by the Company
of this Agreement has been duly authorized by all necessary action on the part of the Company, its shareholders, and its board of directors and this Agreement has been approved by the board of directors of the Company.  This Agreement constitutes the legal,
valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of
creditors’ rights, or (b) as limited by general principles of equity that restrict the availability of equitable remedies.

                        8.2          Non-Contravention; Consents. 
Except as set forth in Part 2.21 of the Disclosure Schedule delivered to SMC and RCT in connection with the Stock Purchase Agreement, neither (1) the execution, delivery or performance of this Agreement, nor (2) the consummation of the transactions contemplated
by this Agreement, will directly or indirectly (with or without notice or lapse of time):

                                        (a)          contravene,
conflict with or result in a violation of (i) any of the provisions of the Company’s Restated Certificate or bylaws, or (ii) any resolution adopted by the Company’s shareholders, the Company’s board of directors or any committee of the
Company’s board of directors;

                                        (b)          contravene,
conflict with or result in a violation of, or give any Governmental Body or other Person the right to challenge any of the transactions contemplated by this Agreement or to exercise any remedy or obtain any relief under, any Legal Requirement or any order, writ,
injunction, judgment or decree to which the Company, or any of the assets owned or used by the Company, is subject;

                                        (c)          contravene,
conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company or that otherwise relates to
the Company’s business or to any of the assets owned or used by the Company;

                                        (d)          contravene,
conflict with or result in a violation or breach of, or result in a default under, any provision of any Material Contract, or give any Person the right to (i) declare a default or exercise any remedy under any Material Contract, (ii) accelerate
the

8

maturity or performance of any Material Contract, or (iii) cancel, terminate or modify any Material Contract; or

                                        (e)          result
in the imposition or creation of any lien or other Encumbrance upon or with respect to any asset owned or used by the Company (except for minor liens that will not, in any case or in the aggregate, materially detract from the value of the assets subject thereto or
materially impair the operations of the Company).

Except as set forth in Part 2.21 of the Disclosure Schedule delivered to SMC and RCT in connection with the Stock Purchase Agreement, the Company is not and will not be required to make any filing with or give any notice to,
or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement, or (y) the consummation of any of the other transactions contemplated by this Agreement.

          9.          Representations and Warranties of SMC.  SMC hereby represents and warrants to the
Company as follows:

                        9.1          Authorization.  SMC has the
absolute and unrestricted right, power and authority to enter into and perform its obligations under this Agreement.  The execution, delivery and performance by SMC of this Agreement has been duly authorized by all necessary action on the part of SMC.  This
Agreement constitutes the legal, valid and binding obligation of SMC, enforceable against SMC in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting
enforcement of creditors’ rights, or (b) as limited by general principles of equity that restrict the availability of equitable remedies.

          10.          Representations and Warranties of RCT.  RCT hereby represents and warrants to the
Company as follows:

                         10.1          Authorization.  RCT has the
absolute and unrestricted right, power and authority to enter into and perform its obligations under this Agreement.  The execution, delivery and performance by RCT of this Agreement has been duly authorized by all necessary action on the part of RCT.  This
Agreement constitutes the legal, valid and binding obligation of RCT, enforceable against RCT in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting
enforcement of creditors’ rights, or (b) as limited by general principles of equity that restrict the availability of equitable remedies.

          11.          F2A Milestone.  The “F2A Milestone” means the Company’s creation
of at least one (1) transgenic rabbit that meets the following criteria (the criteria being further described in an Appendix to the hTG Collaboration Agreement):

                        
 (a)           the rabbit’s chromosomal DNA contains [**] transgene and [**] transgene (standard PCR assays will be used to determine the presence of the transgenes);

**     This redacted material has been omitted pursuant to a request for confidential treatment, and the material has been filed separately with the Securities and Exchange Commission.

9

                        
 (b)           the rabbit expresses functional Humanized Antibodies of the [**] after immunization with [**] at a level similar or better to non-engineered, non-transgenic rabbits immunized with [**]
(standard ELISA assays will be used to determine the level of functionality); 

                         (c)           the
rabbit expresses functional Humanized Antibodies of the [**] after immunization with [**] at a level similar or better to non-engineered, non-transgenic rabbits immunized with [**] will be used to determine the level of functionality); and

                         (d)          
after immunization of the rabbit with [**]: (i) Humanized Antibodies of the [**] are present in the serum of the transgenic rabbit at a concentration of [**] of Humanized Antibody (standard ELISA assays will be used to measure the concentration of Humanized
Antibodies); and (ii) [**] immunoglobulin levels in the blood are [**]% of the comparable levels of Humanized Antibodies of the [**] in the rabbit (standard ELISA assays will be used to measure comparable levels of antibodies).

          “Humanized Antibody” means an antibody or immunoglobulin that contains [**].

          A description of PCR, ELISA and flow cytometric assays (herein, the “F2A Assays”) to be used above are attached in an Appendix to the hTG Collaboration
Agreement. THP’s and SMC’s responsibilities for performance and time frames for performance of the F2A Assays are set forth in an Appendix to the hTG Collaboration Agreement.

          12.          Termination of Agreement.

                         12.1          Termination.  This
Agreement:

                                           
(a)          may be terminated by SMC and RCT at any time upon joint written notice provided to the Company; and

                                           
(b)          shall automatically terminate without any action on the part of any party hereto on the F2A Option Expiration Date; and

                                           
(c)          shall automatically terminate without any action on the part of any party hereto, as to either SMC, RCT, or both, on the G2A Option Expiration Date, as to any and all such Persons who have then failed
to complete the Series B Closing or the G2A Closing, and acquire the Series B Shares pursuant to the Series B Stock Purchase Agreement or the Stock Purchase Agreement.

          13.          Publicity.  Neither the Company nor RCT shall make any public announcement, press
release or other disclosure with respect to this Agreement or any of the transactions contemplated herein without the prior written approval of SMC, which approval shall not be unreasonably withheld nor unduly delayed, and RCT shall not make any such disclosures
without the prior written approval of the Company, which approval shall not be unreasonably withheld or unduly delayed.  Except to the extent required by applicable securities laws for SMC

**     This redacted material has been omitted pursuant to a request for confidential treatment, and the material has been filed separately with the Securities and Exchange Commission.

10

to remain in compliance with its disclosure obligations thereunder, SMC shall not make any public announcement, press release or other disclosure with respect to the Series B Closing or the Series C Closing under this
Agreement without the prior written approval of the Company, which approval shall not be unreasonably withheld or unduly delayed.  With respect to any disclosures concerning this Agreement required by applicable securities laws, SMC shall provide a copy of any
such proposed disclosures to the Company, and shall provide the Company with an opportunity to comment upon such proposed disclosures, in a reasonable period of time prior to the date such disclosures are required to be made public. 

          14.          Injunctive Relief.  Each of the parties hereto acknowledges that monetary damages
are insufficient to compensate for any breach hereof, and that the measure of damages is difficult to determine.  Accordingly, without limitation on any other remedies that may otherwise be available, if the Company fails to fulfill any obligation under this
Agreement, then each of SMC and RCT, as applicable, shall be entitled to specific performance of the obligations of the Company hereunder.  In addition, the Company shall be jointly and severally liable for the payment of SMC’s and RCT’s, as
applicable, reasonable out-of-pocket expenses (including, without limitation, attorneys’ fees) in connection therewith. 

          15.          Miscellaneous.

                         15.1          Further Assurances.  Each
party hereto shall execute and cause to be delivered to each other party hereto such instruments and other documents, and shall take such other actions, as such other party may reasonably request for the purpose of carrying out or evidencing any of the transactions
contemplated by this Agreement.

                         15.2          Attorneys’ Fees.  In
the event that any suit or action is instituted to enforce any provisions of this Agreement or any Related Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs, and expenses of enforcing such provisions,
including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include without limitation, all fees, costs and expenses of appeals.  A prevailing party shall be deemed to be that party which receives a preponderance of
the relief (excluding any consequential or punitive damages sought) such party was seeking.

                         15.3          Notices.  Any notice or
other communication required or permitted to be delivered to any party under this Agreement shall be in writing and shall be deemed properly delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service or by
facsimile) to the address or facsimile telephone number set forth beneath the name of such party below (or to such other address or facsimile telephone number as such party shall have specified in a written notice given to the other parties hereto):

11

	
(a)

	
                                   

	
if to SMC to:

		
                                   

	
		
                                   

	
SangStat Medical Corporation

 6300 Dumbarton Circle

 Fremont, California 94555

		
                                   

	
Attn: Chief Executive Officer (with a copy to the General Counsel)

		
                                   

	
		
                                   

	
Telephone:______________________________

		
                                   

	
Telecopy:  (510) 798-4493

		
                                   

	
		
                                   

	
with a copy to (which shall not constitute notice):

		
                                   

	
		
                                   

	
Cooley Godward LLP

 Five Palo Alto Square

 3000 El Camino Real

 Palo Alto, California 94306

		
                                   

	
Attn: Barbara Kosacz, Esq.

		
                                   

	
Telephone: (650) 843-5818

		
                                   

	
Telecopy: (650) 849-7400

		
                                   

	
	
(b)

	
                                   

	
If to RCT:

		
                                   

	
		
                                   

	
Research Corporation Technologies, Inc.

 101 North Wilmot Road, Suite 600

 Tucson, Arizona 85711

		
                                   

	
Attn:  Gary M. Munsinger, President

		
                                   

	
Phone:  (520) 748-4411

		
                                   

	
Telecopy:  (520) 748-0025

		
                                   

	
		
                                   

	
With a copy to (which shall not constitute notice):

		
                                   

	
		
                                   

	
Research Corporation Technologies, Inc.

		
                                   

	
101 North Wilmot Road, Suite 600

		
                                   

	
Tucson, Arizona 85711

		
                                   

	
Attn:  Timothy J. Reckart, Esq.

		
                                   

	
Phone:  (520) 748-4456

		
                                   

	
Telecopy:  (520) 748-0025

12

	
(c)

	
                                   

	
If to the Company:

		
                                   

	
		
                                   

	
Therapeutic Human Polyclonals, Inc.

 101 North Wilmot Road, Suite 600

 Tucson, Arizona 85711

		
                                   

	
Attn: Mr. Shaun A. Kirkpatrick

		
                                   

	
Phone: (520) 748-4446

		
                                   

	
Telecopy: (520) 748-0025

		
                                   

	
		
                                   

	
With a copy to (which shall not constitute notice):

		
                                   

	
		
                                   

	
Gammage & Burnham, PLC

 Two N. Central Avenue, Suite 1800

 Phoenix, Arizona 85004

		
                                   

	
Attn:  Kevin R. Merritt, Esq.

		
                                   

	
Telephone:  (602) 256-4481

		
                                   

	
Facsimile:  (602) 256-4475

          15.4          Time of the Essence.  Time is of the essence of this Agreement.

          15.5          Headings. The bold headings contained in this Agreement are for convenience of reference
only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.

          15.6          Counterparts. This Agreement may be executed in several counterparts, each of which
shall constitute an original and all of which, when taken together, shall constitute one agreement.

          15.7          Governing Law. This Agreement shall be construed in accordance with, and governed in all
respects by, the internal laws of the State of California (without giving effect to principles of conflicts of laws).

          15.8          Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of
the parties hereto and their successors and assigns (if any).  The Company shall not assign this Agreement or any rights or obligations hereunder (by operation of law or otherwise) to any Person.  SMC may assign any or all of its rights under this Agreement
to any other Person without obtaining the consent or approval of any other party hereto or of any other Person in connection with (i) a sale of all or substantially all of the assets of SMC to such Person or its affiliates, or (ii) a transaction or series of related
transactions in which the holders of SMC capital stock immediately prior to any such transaction or series of related transactions hold less than 50% of the outstanding voting power of SMC capital stock immediately after such transaction or series of related
transactions.

          15.9          Remedies Cumulative; Specific Performance.  The rights and remedies of the
parties hereto shall be cumulative (and not alternative).  The parties to this Agreement agree that, in the event of any breach or threatened breach by any party to this Agreement of any covenant,

13

obligation or other provision set forth in this Agreement for the benefit of any other party to this Agreement, such other party shall be entitled (in addition to any other remedy that may be available to it) to (a) a
decree or order of specific performance or mandamus to enforce the observance and performance of such covenant, obligation or other provision, and (b) an injunction restraining such breach or threatened breach.

          15.10          Waiver.  No failure on the part of any Person to exercise any power, right,
privilege or remedy under this Agreement, and no delay on the part of any Person in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy and no single or partial exercise of any
such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.  No Person shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or
remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Person; and any such waiver shall not be applicable or have any effect except
in the specific instance in which it is given.

          15.11          Amendments.  This Agreement may not be amended, modified, altered or supplemented
other than by means of a written instrument duly executed and delivered on behalf of:

                             (a)          SMC, RCT and the
Company, if the G2A Closing has not occurred; and

                             (b)          SMC and the Company, if
either (i) the G2A Closing has occurred, or (ii) RCT has not exercised the Primary G2A Option on or before the G2A Required Exercise Date.

          15.12          Severability.  In the event that any provision of this Agreement, or the
application of any such provision to any Person or set of circumstances, shall be determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to Persons or circumstances other than
those as to which it is determined to be invalid, unlawful, void or unenforceable, shall not be impaired or otherwise affected and shall continue to be valid and enforceable to the fullest extent permitted by law.

          15.13          Entire Agreement. This Agreement and the other agreements referred to herein set forth
the entire understanding of the parties hereto relating to the subject matter hereof and thereof and supersede all prior agreements and understandings among or between any of the parties relating to the subject matter hereof and thereof; provided however, that
the Confidentiality Agreement executed by SMC and the Company shall not be superseded by this Agreement and shall remain in effect in accordance with its terms.

14

          15.14          Construction.

                             
(a)          For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the
feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders.

                             
(b)          The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this
Agreement.

                             
(c)          As used in this Agreement, the words “include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by
the words “without limitation.”

                             
(d)          Except as otherwise indicated, all references in this Agreement to “Sections” and “Exhibits” are intended to refer to Sections of this Agreement and Exhibits to this
Agreement.

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

15

                             In Witness Whereof, the parties below have
executed this Option Agreement as of the date first above written.

	
SangStat Medical Corporation

	
                                   

	
Therapeutic Human Polyclonals, Inc.

		
                                   

	
	
By:          /s/ Jean-Jacques Bienaimé                 

	
                                   

	
By:          /s/ Shaun A. Kirkpatrick                    

			
                                   

		
	
Name:     Jean-Jacques Bienaimé                      

	
                                   

	
Name:     Shaun A. Kirkpatrick                          

			
                                   

		
	
Title:       Chairman, President & CEO              

	
                                   

	
Title:      
President                                              

			
                                   

		
		
                                   

	
	
Address:

	
                                   

	
Address:

		
                                   

	
	
6300 Dumbarton Circle

	
                                   

	
101 North Wilmot Drive

	
Fremont, California 94555

	
                                   

	
Suite 600

	
Fax:  (510) 789-4493

	
                                   

	
Tucson, Arizona 85711

	
Attention:  General Counsel

	
                                   

	
Fax:  (520) 748-0025

		
                                   

	
Attention: President/Chief Executive Officer

		
                                   

	
		
                                   

	
Research Corporation Technologies, Inc.

		
                                   

	
		
                                   

	
By:          /s/ Gary M.
Munsinger                      

		
                                   

		
		
                                   

	
Name:     Gary M.
Munsinger                            

		
                                   

		
		
                                   

	
Title:      
President                                              

		
                                   

		
		
                                   

	
		
                                   

	
Address:

		
                                   

	
		
                                   

	
101 North Wilmot Road

		
                                   

	
Suite 600

		
                                   

	
Tucson, Arizona 85711

		
                                   

	
Fax: (520) 748-0025

		
                                   

	
Attention: General Counsel

16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00048-of-00352.parquet"}]]